MSCV mouse Vav1DN IRES GFP
(Plasmid
#107092)
-
PurposeMammalian expression retroviral vector
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 107092 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backboneMSCV
- Backbone size w/o insert (bp) 6673
-
Vector typeMammalian Expression, Retroviral
-
Selectable markersGFP
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameVav1 dominant negative cDNA
-
SpeciesM. musculus (mouse)
-
Insert Size (bp)558
-
MutationAA 1-186
-
Entrez GeneVav1 (a.k.a. Vav, vav-T)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site BamHI (unknown if destroyed)
- 3′ cloning site XhoI (unknown if destroyed)
- 5′ sequencing primer unknown (Common Sequencing Primers)
Resource Information
-
A portion of this plasmid was derived from a plasmid made byThe Vav1 cDNA came from Dr. S. Katzav, Hebrew University, Jerusalem, Israel
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
MSCV mouse Vav1DN IRES GFP was a gift from Martine Roussel (Addgene plasmid # 107092 ; http://n2t.net/addgene:107092 ; RRID:Addgene_107092) -
For your References section:
Cross-species epigenetics identifies a critical role for VAV1 in SHH subgroup medulloblastoma maintenance. Lindsey JC, Kawauchi D, Schwalbe EC, Solecki DJ, Selby MP, McKinnon PJ, Olson JM, Hayden JT, Grundy RG, Ellison DW, Williamson D, Bailey S, Roussel MF, Clifford SC. Oncogene. 2015 Sep 3;34(36):4746-57. doi: 10.1038/onc.2014.405. Epub 2014 Dec 22. 10.1038/onc.2014.405 PubMed 25531316